Financhill
Sell
44

DK Quote, Financials, Valuation and Earnings

Last price:
$16.95
Seasonality move :
8.24%
Day range:
$16.93 - $17.59
52-week range:
$13.40 - $33.60
Dividend yield:
5.99%
P/E ratio:
--
P/S ratio:
0.09x
P/B ratio:
3.39x
Volume:
2.5M
Avg. volume:
1.9M
1-year change:
-44.78%
Market cap:
$1.1B
Revenue:
$11.9B
EPS (TTM):
-$8.84

Analysts' Opinion

  • Consensus Rating
    Delek US Holdings has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 8 Hold ratings, and 3 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $19.00, Delek US Holdings has an estimated upside of 12.16% from its current price of $16.94.
  • Price Target Downside
    According to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $16.94.

Fair Value

  • According to the consensus of 12 analysts, Delek US Holdings has 12.16% upside to fair value with a price target of $19.00 per share.

DK vs. S&P 500

  • Over the past 5 trading days, Delek US Holdings has overperformed the S&P 500 by 7.56% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Delek US Holdings does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Delek US Holdings revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter Delek US Holdings reported revenues of $2.4B.

Earnings Growth

  • Delek US Holdings has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Delek US Holdings reported earnings per share of -$6.55.
Enterprise value:
3.4B
EV / Invested capital:
--
Price / LTM sales:
0.09x
EV / EBIT:
13.41x
EV / Revenue:
0.28x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
-6.74x
Price / Operating cash flow:
3.64x
Enterprise value / EBITDA:
10.38x
Gross Profit (TTM):
-$200K
Return On Assets:
-8.01%
Net Income Margin (TTM):
-4.65%
Return On Equity:
-62.29%
Return On Invested Capital:
-15.91%
Operating Margin:
-8.92%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $19.8B $16.7B $12.1B $3.9B $2.4B
Gross Profit $736.5M $605.7M -$200K -$49.7M -$140.8M
Operating Income $426.3M $278.7M -$256.2M -$126.3M -$211.8M
EBITDA $792.6M $690.5M -$6M -$41.4M -$287.1M
Diluted EPS $3.51 $0.22 -$8.84 -$2.57 -$6.55
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $2.3B $3B $3.7B $2.7B $2.3B
Total Assets $6.1B $6.8B $8.2B $7.2B $6.7B
Current Liabilities $1.9B $3.1B $3.1B $2.7B $2.5B
Total Liabilities $5B $5.8B $7.1B $6.2B $6.1B
Total Equity $1.1B $1B $1.1B $959.7M $575.2M
Total Debt $2.3B $2.2B $3.1B $2.6B $2.8B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Cash Flow Statement
Cash Flow Operations $425.3M $1B -$66.8M $90.8M -$163.5M
Cash From Investing -$931.6M -$408M -$241.5M -$69.4M -$215.8M
Cash From Financing $491.1M -$624.7M $221.7M -$100.9M $77.3M
Free Cash Flow $139.5M $616.8M -$497.4M $16.9M -$355.3M
DK
Sector
Market Cap
$1.1B
$62.4M
Price % of 52-Week High
50.42%
61%
Dividend Yield
5.99%
0%
Shareholder Yield
-18.92%
4.69%
1-Year Price Total Return
-44.79%
-22.46%
Beta (5-Year)
1.142
1.027
Dividend yield:
5.99%
Annualized payout:
$1.01
Payout ratio:
-11.46%
Growth streak:
2 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $16.05
200-day SMA
Sell
Level $19.58
Bollinger Bands (100)
Sell
Level 16.19 - 19.07
Chaikin Money Flow
Sell
Level -2.1M
20-day SMA
Buy
Level $15.78
Relative Strength Index (RSI14)
Buy
Level 54.98
ADX Line
Buy
Level 13.78
Williams %R
Sell
Level -18.9003
50-day SMA
Sell
Level $17.54
MACD (12, 26)
Buy
Level 2.43
25-day Aroon Oscillator
Sell
Level -60
On Balance Volume
Sell
Level -1.2M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (1.6212)
Sell
CA Score (Annual)
Level (-1.9591)
Buy
Beneish M-Score (Annual)
Level (-6.7059)
Sell
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.2615)
Sell
Piotroski F Score (Annual)
Level (2)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Delek US Holdings Inc is an integrated energy business focused on petroleum refining, transportation and storage; wholesale crude oil, intermediate, and refined products, and convenience stores retailing. The company owns and operates independent refineries that produce a variety of petroleum products for transportation and industrial markets in the United States. It has three segments: Refining segment and Logistics segment. The logistics segment generates revenue through gathering, transporting, and storing crude oil and intermediate products, as well as by marketing, storing, and distributing refined products. The company also offers a collection of retail fuel and convenience stores operating in the Southeast region of the United States.

Stock Forecast FAQ

In the current month, DK has received 1 Buy ratings 8 Hold ratings, and 3 Sell ratings. The DK average analyst price target in the past 3 months is $19.00.

  • Where Will Delek US Holdings Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Delek US Holdings share price will rise to $19.00 per share over the next 12 months.

  • What Do Analysts Say About Delek US Holdings?

    Analysts are divided on their view about Delek US Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Delek US Holdings is a Buy and believe this share price will drop from its current level to $25.00.

  • What Is Delek US Holdings's Price Target?

    The price target for Delek US Holdings over the next 1-year time period is forecast to be $19.00 according to 12 Wall Street analysts, 1 of them rates the stock a Buy, 3 rate the stock a Sell, and 8 analysts rate the stock a Hold.

  • Is DK A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Delek US Holdings is a Hold. 8 of 12 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of DK?

    You can purchase shares of Delek US Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Delek US Holdings shares.

  • What Is The Delek US Holdings Share Price Today?

    Delek US Holdings was last trading at $16.95 per share. This represents the most recent stock quote for Delek US Holdings. Yesterday, Delek US Holdings closed at $16.94 per share.

  • How To Buy Delek US Holdings Stock Online?

    In order to purchase Delek US Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Tenable Stock a Buy, Sell or Hold?
Is Tenable Stock a Buy, Sell or Hold?

Tenable (NASDAQ:TENB) is a cybersecurity company with a focus on…

Is CyberArk Stock a Buy, Sell or Hold?
Is CyberArk Stock a Buy, Sell or Hold?

CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…

Is Amazon Stock Still Worth Staking On?
Is Amazon Stock Still Worth Staking On?

Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…

Stock Ideas

Buy
55
Is AAPL Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 36x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Sell
50
RGC alert for Mar 22

Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.

Sell
36
VMI alert for Mar 22

Valmont Industries [VMI] is down 12.54% over the past day.

Buy
61
ALNY alert for Mar 22

Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock